Very well said. And its factual. Imagine if Neil Woodfrod invested 100 million so far in one of AFs or Cramers picks, it would be all over the screen, CEO interviewed and be trading at $80. I lost all objectivity with Cramer and so have many by his insistance on not interviewing Linda. I cringe when an audience member calls the show and thanks Cramer. Holding back the truth (NWBO results) is one of the biggest lies a man can make. Read the Bible for that quote !
all over the world.
anatabine citrate is a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. The Company has sponsored extensive pre-clinical (in vitro and in vivo) studies resulting in peer reviewed and published scientific journal articles, covering models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune Thyroiditis. All these studies demonstrated the anti-inflammatory effects of anatabine.
Quotient Clinical, the Company's UK-based outsourced partner will immediately begin recruitment of healthy volunteers, with dosing to commence in February 2015, and with initial formulation PK data to emerge shortly after. Although study data management and analysis are expected to continue into August 2015, the Company anticipates having a substantial amount of data by MID-YEAR,
He sees no risk and has assisted in mergers in major biotechs before. Going UP!
Late stage cancers. Havent seen any better news at ASCO.
I have not seen such childish behavior fom internet bloggers etc. protecting their circle of friends. And the children on the cable channel, well they are just wealthier kids who kick and scream when they don't get their way. No wonder ratings continue to slide. Grow up. And if you believe in God, make him proud and disclosure that you are assisting those shorts you are friendly with. You are hurting us smaller investors by shorting and then say you are helping us on TV with only the advice you wish to share.
Clinical data from the first three cohorts will be discussed. Cohort 3, which included 3 additional patients, demonstrated no dose limiting toxicities in patients older than 60 and up to 87 years of age who were not eligible for currently approved therapies. Two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery (CRi). These responses were documented in the settings of high pre-treatment leukemia burdens of up to 88% in the bone marrow.
News is too late for abstrat..uually the best type of news at ASCO. Woodford will be watching and all his long hedge fund friends,
This is cheap!!
Acually NWBO is sponsoring and thus I do agree they will have lots to say to BIG MONEY.
Multiple cancer treatment with amazing success in US, Uk and Germany. $35+
I think major bios want to team up with NWBO..stay tuned.
Add on news from MWBO and we explode !!